Lowering the colorectal cancer screening age improves predicted outcomes in a microsimulation model

References

• Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544–573.
   PubMed Web of Science ®Google Scholar
• Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med. 2013;369(12):1106–1114.
   PubMed Web of Science ®Google Scholar
• U.S. Preventive Services Task Force. Colorectal cancer: screening draft recommendation statement. Rockville, MD: U.S. Preventive Services Task Force; 2020. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/draft-recommendation/colorectal-cancer-screening3
   Google Scholar
• Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68(4):250–281.
   PubMed Web of Science ®Google Scholar
• Bibbins-Domingo K, Grossman DC, Curry SJ, US Preventive Services Task Force, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2016;315(23):2564–2575.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Fedewa SA, Anderson WF, et al. Colorectal cancer incidence patterns in the United States. J Natl Cancer Inst. 2017;109(8):1974–2013.
   Google Scholar
• Bailey CE, Hu CY, You YN, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975–2010. JAMA Surg. 2015;150(1):17–22.
   PubMed Web of Science ®Google Scholar
• Shaukat A, Kahi CJ, Burke CA, et al. ACG clinical guidelines: colorectal cancer screening 2021. Am J Gastroenterol. 2021;116(3):458–479.
   PubMed Web of Science ®Google Scholar
• Knudsen AB, Zauber AG, Rutter CM, et al. Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US Preventive Services Task Force. JAMA. 2016;315(23):2595–2609.
   PubMed Web of Science ®Google Scholar
• Peterse EFP, Meester RGS, Siegel RL, et al. The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: Microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline. Cancer. 2018;124(14):2964–2973.
   PubMed Web of Science ®Google Scholar
• Ladabaum U, Mannalithara A, Meester RGS, et al. Cost-effectiveness and national effects of initiating colorectal cancer screening for average-risk persons at age 45 years instead of 50 years. Gastroenterology. 2019;157(1):137–148.
   PubMed Web of Science ®Google Scholar
• Zauber AG, Knudsen AB, Rutter C, et al. Evaluating the benefits and harms of colorectal cancer screening strategies: a collaborative modeling approach. Rockville, (MD): Agency for Healthcare Research and Quality; 2015. Available from: https://www.uspreventiveservicestaskforce.org/Home/GetFile/1/16540/cisnet-draft-modeling-report/pdf
   Google Scholar
• de Moor JS, Cohen RA, Shapiro JA, et al. Colorectal cancer screening in the United States: trends from 2008 to 2015 and variation by health insurance coverage. Prev Med. 2018;112:199–206.
   PubMed Web of Science ®Google Scholar
• Inadomi JM, Vijan S, Janz NK, et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med. 2012;172(7):575–582.
   PubMedGoogle Scholar
• Jensen CD, Corley DA, Quinn VP, et al. Fecal immunochemical test program performance over 4 rounds of annual screening: a retrospective cohort study. Ann Intern Med. 2016;164(7):456–463.
   PubMed Web of Science ®Google Scholar
• Rastogi N, Xia Y, Inadomi JM, et al. Disparities in colorectal cancer screening in New York City: an analysis of the 2014 NYC community health survey. Cancer Med. 2019;8(5):2572–2579.
   PubMed Web of Science ®Google Scholar
• Piscitello A, Saoud L, Fendrick AM, et al. Estimating the impact of differential adherence on the comparative effectiveness of stool-based colorectal cancer screening using the CRC-AIM microsimulation model. PLOS One. 2020;15(12):e0244431.
   PubMed Web of Science ®Google Scholar
• Piscitello A, Saoud L, Matney M, et al. Description and validation of the colorectal cancer and adenoma incidence & mortality (CRC-AIM) microsimulation model 2020. Available from: https://www.biorxiv.org/content/10.1101/2020.03.02.966838v1
   Google Scholar
• Weiser E, Parks P, Swartz RK, et al. Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening: real-world data from a large cohort of older adults. J Med Screen. 2021;28(1):18–24.
   PubMed Web of Science ®Google Scholar
• Akram A, Juang D, Bustamante R, et al. Replacing the guaiac fecal occult blood test with the fecal immunochemical test increases proportion of individuals screened in a large healthcare setting. Clin Gastroenterol Hepatol. 2017;15(8):1265–1270.e1.
   PubMed Web of Science ®Google Scholar
• Hassan C, Giorgi Rossi P, Camilloni L, HTA Group, et al. Meta-analysis: adherence to colorectal cancer screening and the detection rate for advanced neoplasia, according to the type of screening test. Aliment Pharmacol Ther. 2012;36(10):929–940.
   PubMed Web of Science ®Google Scholar
• Megna B, Shaukat A. Is 45 the new 50? Controversies in lowering the screening age for colorectal cancer. Expert Rev Gastroenterol Hepatol. 2019;13(10):915–917.
   PubMed Web of Science ®Google Scholar
• Goede SL, Kuntz KM, van Ballegooijen M, et al. Cost-savings to Medicare from pre-Medicare colorectal cancer screening. Med Care. 2015;53(7):630–638.
   PubMed Web of Science ®Google Scholar
• Jung YS, Park CH, Kim NH, et al. Colorectal cancer screening with the fecal immunochemical test in persons aged 30 to 49 years: focusing on the age for commencing screening. Gastrointest Endosc. 2017;86(5):892–899.
   PubMed Web of Science ®Google Scholar
• Imperiale TF, Kisiel JB, Itzkowitz SH, et al. Specificity of the multi-target stool DNA test for colorectal cancer screening in average-risk 45–49 year-olds: a cross-sectional study. Cancer Prev Res. 2021;14(4):489–496.
   PubMed Web of Science ®Google Scholar
• Martin J, Halm EA, Tiro JA, et al. Reasons for lack of diagnostic colonoscopy after positive result on fecal immunochemical test in a safety-net health system. Am J Med. 2017;130(1):93 e1–93 e7.
   PubMed Web of Science ®Google Scholar
• May FP, Yano EM, Provenzale D, et al. Barriers to follow-up colonoscopies for patients with positive results from fecal immunochemical tests during colorectal cancer screening. Clin Gastroenterol Hepatol. 2019;17(3):469–476.
   PubMed Web of Science ®Google Scholar